Resource Library
Cerba Research has conducted ~80 hematological malignancy trials within the last 5 years alone. Download our fact sheet and discover our hematological malignancies trial portfolio with cutting-edge laboratory solutions.
Reach out to our experts and discover how we can help advance your research
Contact Us
Resource Library
COVID-19 accelerated infectious disease R&D, but timelines and funding are now normalizing. Persistent operational barriers remain, and improved surveillance and communication are needed to enhance vaccine development and trial efficiency.
Our roundtable report from the World Vaccine Congress 2024 discusses the evolving landscape for infectious disease clinical trials, the operational barriers for therapeutics and vaccine development, and why improving epidemiologic surveillance and communication are critical to strengthening site and patient enrollment in clinical trials.
Reach out to our experts and discover how we can help you advance your clinical trial
Contact Us
Resource Library
Cerba Research offers specialized HPV SPF10 PCR-detection/typing kits tailored to detect and identify HPV genotypes in vaccine and epidemiology studies. Our HPV vaccine research capabilities ensure comprehensive analysis and accurate identification of relevant genotypes. Take a look at our brochure and discover how our assay excels in analyzing HPV in formalin-fixed-paraffin embedded (FFPE) tissues, facilitating a correlation between histological findings and specific HPV genotypes.
Reach out to our experts and discover how we can help you advance your clinical trial
Contact Us
Resource Library
Cerba Research has conducted nearly 200 oncology trials within the last 5 years alone, with 55%+ being solid tumors such as lung, breast, and colorectal cancers. The central and specialty laboratories’ expertise includes specialized assays such as next-generation sequencing (NGS), flow cytometry (FCM), immunohistochemistry (IHC), AI in image analysis, and NanoString®. Check our latest fact sheet to learn more about our highlights and capabilities.
Reach out to our experts and discover how we can help advance your research
Contact Us
Resource Library
Cerba Research has conducted nearly 200 oncology trials within the last 5 years alone. Its experience extends to both solid and liquid tumors and includes specialized assays such as next-generation sequencing (NGS), flow cytometry (FCM), immunohistochemistry (IHC), and NanoString®. Check our latest fact sheet to learn more about our highlights and capabilities.
Reach out to our experts and discover how we can help advance your research
Contact Us
Resource Library
Experience the unparalleled activity of Cerba Research’s Infectious Diseases (ID) therapy sector, boasting a remarkable track record of over 600 executed trials in just the last 5 years.
Reach out to our experts and discover how we can help advance your research
Contact Us
Resource Library
Discover the extraordinary world of rare diseases, where uniqueness defines the landscape. While these conditions may lack a singular definition, they encompass a myriad of fascinating conditions waiting to be understood and treated.
Reach out to our experts and discover how we can help advance your research
Contact Us
Resource Library
Although it is an important biomarker in oncology (mostly in breast and prostate), Ki-67 immunohistochemistry (IHC) analysis has yet to be standardized. Working groups have provided guidelines for Ki-67 scoring in different cancer types to limit pathologist’s variability.
Digital analysis solutions to assist scoring with image analysis or artificial intelligence (AI) have recently emerged in the evaluation of Ki-67 as rapid and robust solutions. In this context, we compared the results of Ki-67 scoring performed with Aiforia Platform ® (AI platform) and Halo ® (image analysis supervised software) against three independent pathologists on various solid tumors.
Discover more about this in the case study.
Reach out to our experts and see how we can transform research and advance health together
Contact Us
Resource Library
In the ever-evolving landscape of healthcare, Cell and Gene Therapy (CGT) stands at the forefront of groundbreaking advancements. With the power to precisely manipulate cells and genes for therapeutic purposes, CGT offers immense promise in treating diseases at their root.
In the whitepaper “Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio.” we dive into the critical realm of patient safety within CGT. Authored by industry experts, this comprehensive guide presents a novel approach to patient safety monitoring, fusing breakthroughs in flow cytometry and genomics solutions.
Key Topics Covered:
🔍 Understanding the Risks: Ensuring Patient Safety: As CGT continues to revolutionize medicine, it’s imperative to acknowledge the inherent risks associated with these therapies. From the potential for insertional oncogenesis to the emergence of replication-competent viruses, safeguarding patient safety remains paramount.
📊 Key Capabilities: Vector Copy Number (VCN) Testing, Viral Integration Site (VIS) Analysis, Replication Competent Virus Testing, Immunophenotyping and Enumeration.
⚖️ FDA Concerns: FDA’s requirements to ensure safety and adverse events
Reach out to our experts and discover how we can help you transform your research and advance health in the field of immune repertoire sequencing.
Contact Us
Resource Library
Cerba Research Montpellier (CRM), a leader in histopathology and part of the Cerba Research group, is revolutionizing solid tumor clinical trials with our cutting-edge NanoString® platforms. Specializing in multiplex immunofluorescence for FFPE tissues, our lab now offers unparalleled transcriptomic and proteomic analysis capabilities.
Our recent acquisition of NanoString® technology enhances precision in solid tumor research. We have validated RNA analysis protocols for both bulk analysis using nCounter and spatial analysis with the GeoMx DSP platform’s whole transcriptome atlas (WTA). This advancement opens new doors in cancer research, extending potentially to other therapeutic areas.
Delve deeper into our innovative approach and its impact on solid tumor clinical trials by exploring our poster from SITC 2023. It showcases our advanced techniques and their applications in transformative cancer research.
Reach out to our experts and discover how we can transform research and advance health together
Contact Us
